The aim of this study was to determine the prevalence of in vitro resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. The National Committee for Clinical Laboratory Standards' broth microdilution method was used to determine the sensitivities to fluconazole, itraconazole, ketoconazole, and nystatin, whilst the Etest® method was used to determine the sensitivity to amphotericin B. The prevalence of in vitro resistance was: amphotericin B, 2%; fluconazole, 8%; itraconazole, 22%; ketoconazole, 7%; nystatin, 0%. Moreover, 28% of the yeasts was resistant to one or more of the azole group of anti-fungal drugs. The results of this study suggest that azole resistance may become a clinical problem in palliative care.
Standing Medical Advisory Committee Sub-Group on Antimicrobial Resistance (UK). The path of least resistance. London: Department of Health, 1998.
2.
Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis1995; 21: 897–904.
3.
Espinel-Ingroff A, White T, Pfaller MA. Antifungal agents and susceptibility tests. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH eds. Manual of clinical microbiology, seventh edition. Washington, DC: ASM Press, 1999: 1640–1652.
4.
White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev1998; 11: 382–402.
5.
Finlay IG. Oral symptoms and Candida in the terminally ill. BMJ1986; 292: 592–593.
6.
Clarke JMG, Wilson JA, von Haacke NP, Milne LJR. Oral candidiasis in terminal illness. Health Bull (Edinb)1987; 45: 268–271.
7.
Jobbins J, Bagg J, Parsons K, Finlay I, Addy M, Newcombe RG. Oral carriage of yeasts, coliforms and staphylococci in patients with advanced malignant disease. J Oral Pathol Med1992; 21: 305–308.
8.
Sweeney MP, Bagg J, Baxter WP, Aitchison TC. Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol1998; 34: 123–126.
9.
Fulton P, Phillips P. Fluconazole resistance during suppressive therapy of AIDS-related thrush and esophagitis caused by Candida albicans. In 6th International Conference on AIDS, San Francisco, USA, June 1990 (Abstract ThB468).
10.
Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis1997; 16: 261–280.
11.
Samaranayake LP, MacFarlane TW, Lamey P-J, Ferguson MM. A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol1986; 15: 386–388.
12.
Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol1996; 34: 58–61.
13.
Buesching WJ, Kurek K, Roberts GD. Evaluation of the modified API 20 C system for identification of clinically important yeasts. J Clin Microbiol1979; 9: 565–569.
14.
Bougnoux ME, Dupont C, Mateo J, et al. Serum is more suitable than whole blood for diagnosis of systemic candidiasis by nested PCR. J Clin Microbiol1999; 37: 925–930.
15.
Kurtzman CP, Robnett CJ. Identification of clinically important ascomycetous yeasts based on nucleotide divergence in the 50 end of the large-subunit (26S) ribosomal DNA gene. J Clin Microbiol1997; 35: 1216–1223.
16.
National Committee for Clinical Laboratory Standards (US). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27-A. Wayne: NCCLS, 1997.
17.
Wanger A, Mills K, Nelson PW, Rex JH. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother1995; 39: 2520–2522.
18.
Van Eldere J, Joosten L, Verhaeghe A, Surmont I. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with Etest and semiautomated broth microdilution test. J Clin Microbiol1996; 34: 842–847.
19.
Pfaller MA, Messer SA, Bolmstrom A. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis1998; 32: 223–227.
20.
Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis1997; 24: 235–247.
21.
Ball K, Sweeney MP, Baxter WP, Bagg J. Fluconazole sensitivities of Candida species isolated from the mouths of terminally ill cancer patients. Am J Hospice Palliat Care1998; 15: 315–319.
